TY - JOUR
T1 - Hormona adrenocorticotropa en pacientes con síndrome de West y progresión al síndromedeLennox-Gastaut
AU - Campos-Olazabal, Patricia
AU - Hurtado-Roca, Yamilee
AU - Montúfar-Crespoc, S. Marcela
N1 - Publisher Copyright:
© 2021 Medical Body of the Almanzor Aguinaga Asenjo National Hospital. All Rights Reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Background: This paper will evaluate the use of adrenocorticotropic hormone as a therapy modality for West syndrome and the time required for development of the severely progressive form of West syndrome (LGS, Lennox-Gastaut syndrome). There is little data on this condition for our population. Material and Methods: This is a cohort review in which 139 patient records were evaluated in two pediatric units in Lima, Peru; and they were analyzed between 2000 and 2010. All patients who met the following criteria were included in the study: massive spasms, delayed psychomotor development, and hypsarrhythmia in electroencephalogram (EEG) tracing. Adrenocorticotropic hormone was administered to a group of patients as post-diagnosis therapy. The follow-up period for these patients was 10 years. Results: The hazard ratio (HR) for progression to Lennox-Gastaut Syndrome in patients using adrenocorticotropic hormone was 0.45 (95% CI: 0.24-0.83, p= 0.011) compared to those without adrenocorticotropic hormone. Adjusted RR for progression to Lennox-Gastaut Syndrome for all variables studied (age of onset, sex, frequency of seizures, etiology, and time from diagnosis to therapy initiation) in patients who used adrenocorticotropic hormone was 0.56 (95% CI 0.29 to 0.08, P= 0.085) compared with those without adrenocorticotropic hormone. Conclusions: The use of adrenocorticotropic hormone in patients with West syndrome could protect against progression to Lennox-Gastaut syndrome. We consider this supports the evidence found in populations similar to ours, and we believe this finding could be confirmed with clinical trials.
AB - Background: This paper will evaluate the use of adrenocorticotropic hormone as a therapy modality for West syndrome and the time required for development of the severely progressive form of West syndrome (LGS, Lennox-Gastaut syndrome). There is little data on this condition for our population. Material and Methods: This is a cohort review in which 139 patient records were evaluated in two pediatric units in Lima, Peru; and they were analyzed between 2000 and 2010. All patients who met the following criteria were included in the study: massive spasms, delayed psychomotor development, and hypsarrhythmia in electroencephalogram (EEG) tracing. Adrenocorticotropic hormone was administered to a group of patients as post-diagnosis therapy. The follow-up period for these patients was 10 years. Results: The hazard ratio (HR) for progression to Lennox-Gastaut Syndrome in patients using adrenocorticotropic hormone was 0.45 (95% CI: 0.24-0.83, p= 0.011) compared to those without adrenocorticotropic hormone. Adjusted RR for progression to Lennox-Gastaut Syndrome for all variables studied (age of onset, sex, frequency of seizures, etiology, and time from diagnosis to therapy initiation) in patients who used adrenocorticotropic hormone was 0.56 (95% CI 0.29 to 0.08, P= 0.085) compared with those without adrenocorticotropic hormone. Conclusions: The use of adrenocorticotropic hormone in patients with West syndrome could protect against progression to Lennox-Gastaut syndrome. We consider this supports the evidence found in populations similar to ours, and we believe this finding could be confirmed with clinical trials.
KW - Adrenocorticotropic Hormone
KW - Epilepsy
KW - Lennox-Gastaut Syndrome
UR - http://www.scopus.com/inward/record.url?scp=85132597528&partnerID=8YFLogxK
U2 - 10.35434/rcmhnaaa.2021.144.1322
DO - 10.35434/rcmhnaaa.2021.144.1322
M3 - Artículo
AN - SCOPUS:85132597528
SN - 2225-5109
VL - 14
SP - 466
EP - 471
JO - Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
JF - Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
IS - 4
ER -